The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $4.74

Today's change-0.03 -0.63%
Updated August 26 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $4.74

Today's change-0.03 -0.63%
Updated August 26 4:00 PM -4GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc down (U.S.)$0.03

Merrimack Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$0.03 or 0.63% to (U.S.)$4.74. Over the last five days, shares have lost 4.63% and sit 2.60% above their 52-week low. This security has underperformed the S&P 500 by 64.80% during the last year.

Key company metrics

  • Open(U.S.) $4.74
  • Previous close(U.S.) $4.77
  • High(U.S.) $4.88
  • Low(U.S.) $4.62
  • Bid / Ask(U.S.) $4.58 / (U.S.) $5.08
  • YTD % change-40.00%
  • Volume2,168,640
  • Average volume (10-day)1,726,175
  • Average volume (1-month)2,023,965
  • Average volume (3-month)1,826,906
  • 52-week range(U.S.) $4.62 to (U.S.) $11.00
  • Beta1.99
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.53
Updated August 26 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.06%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue34212116
Total other revenue--------
Total revenue34212116
Gross profit322121--
Total cost of revenue210--
Total operating expense64516455
Selling / general / administrative21181917
Research & development41334538
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-30-30-43-38
Interest income (expense), net non-operating-21-9-6-4
Gain (loss) on sale of assets--------
Other--------
Income before tax-51-39-48-42
Income after tax-51-39-48-42
Income tax, total--------
Net income-51-38-48-43
Total adjustments to net income--------
Net income before extra. items-51-38-48-43
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-51-38-48-43
Inc. avail. to common incl. extra. items-51-38-48-43
Diluted net income-51-38-48-43
Dilution adjustment----0--
Diluted weighted average shares126116116112
Diluted EPS excluding extraordinary itemsvalue per share-0.40-0.33-0.41-0.38
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.40-0.33-0.41-0.38